Glioblastoma (GBM)  
Brain Cancer Research

National Cancer Institute researchers in Bethesda, Maryland, are enrolling participants in the very first study of its kind for a type of brain cancer called glioblastoma or GBM. This research study is testing if adding 1-2 experimental therapies (HSPPC-96 or placebo vaccine and pembrolizumab) improves standard treatment for GBM. All treatment and research procedures are provided at no cost. Travel assistance provided for enrolled participants.

During the study:
• After brain surgery at the NIH to remove as much of the tumor as possible, patients will receive the standard treatment for GBM: radiation treatment, and temozolomide (TMZ), an oral chemotherapy drug.
• All patients will also receive an immunotherapy agent called pembrolizumab. The combination of pembrolizumab with standard treatment has been shown to be well-tolerated.
• Some patients will also receive a vaccine made from part of their own tumor. Researchers want to see if adding this personalized cancer vaccine (HSPPC-96) will improve the effect of pembrolizumab.

You may be eligible if you:
• Are an adult who has been recently diagnosed with GBM or have a suspected GBM and are eligible to undergo surgery at the NIH
• Have not already received radiation, chemotherapy or carmustine wafers for your GBM

For more information, call:
Office of Patient Recruitment  
1-800-411-1222
TTY: 1-866-411-1010
Online: https://go.usa.gov/xNsZb
(NIH study #17-C-0034 or NCT03018288)

Location: The NIH Clinical Center, America’s Research Hospital, is located in Bethesda, Maryland, on the Metro red line (Medical Center stop).